Barbieri Federica, Bajetto Adriana, Porcile Carola, Pattarozzi Alessandra, Schettini Gennaro, Florio Tullio
Section of Pharmacology, Department of Oncology Biology and Genetics, University of Genova, Genova, Italy.
J Mol Endocrinol. 2007 Mar;38(3):383-9. doi: 10.1677/JME-06-0014.
Chemokines are key factors involved in the regulation of immune response, through the activation and control of leukocyte traffic, lymphopoiesis and immune surveillance. However, a large number of chemokines and their receptors are expressed in central nervous system (CNS) cells, either constitutively or induced by inflammatory stimuli, playing a role in many neuropathological processes. Stromal cell-derived factor 1 (SDF1) is a chemokine whose extra-immunological localization and functions have been extensively studied. SDF1 and its receptor CXCR4 were identified in both neurons and glia of many brain areas, including the hypothalamus, as well as at the pituitary level. Importantly, SDF1 and CXCR4 expression is increased in brain tumors in which their activity induced tumor cell proliferation and brain parenchyma invasion. Despite their localization, to date very few reports addressed the role of CXCR4 and SDF1 in the modulation of the hypothalamus/pituitary axis and their possible involvement in the development of pituitary adenomas. In this review, we discuss previous literature data on the role of chemokines in normal and adenomatous pituitary cells, focusing on recent data from our group showing that CXCR4 activation controls proliferation and both prolactin and GH release in the pituitary adenoma cell line GH4C1 through a complex network of intracellular signals. Thus, the SDF1/CXCR4 system together with other chemokinergic ligand-receptor pairs, may represent a novel regulatory pathway for pituitary function and, possibly, be involved in pituitary adenoma development. These lines of evidence suggest that the inhibition of chemokine receptors may represent a novel pharmacological target for the treatment of pituitary adenomas.
趋化因子是参与免疫反应调节的关键因素,可通过激活和控制白细胞运输、淋巴细胞生成及免疫监视来实现。然而,大量趋化因子及其受体在中枢神经系统(CNS)细胞中组成性表达或由炎症刺激诱导表达,在许多神经病理过程中发挥作用。基质细胞衍生因子1(SDF1)是一种趋化因子,其非免疫定位和功能已得到广泛研究。在包括下丘脑在内的许多脑区的神经元和神经胶质细胞以及垂体水平均鉴定出了SDF1及其受体CXCR4。重要的是,在脑肿瘤中SDF1和CXCR4的表达增加,其活性可诱导肿瘤细胞增殖和脑实质浸润。尽管它们有这样的定位,但迄今为止,很少有报道探讨CXCR4和SDF1在下丘脑/垂体轴调节中的作用及其可能参与垂体腺瘤发生的情况。在本综述中,我们讨论了先前关于趋化因子在正常和腺瘤性垂体细胞中作用的文献数据,重点关注我们团队的最新数据,这些数据表明CXCR4激活通过复杂的细胞内信号网络控制垂体腺瘤细胞系GH4C1的增殖以及催乳素和生长激素的释放。因此,SDF1/CXCR4系统与其他趋化因子配体 - 受体对一起,可能代表垂体功能的一种新型调节途径,并可能参与垂体腺瘤的发生。这些证据表明,抑制趋化因子受体可能代表治疗垂体腺瘤的一种新型药理学靶点。